{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:20:06Z","timestamp":1793701206656,"version":"4.5.1"},"reference-count":51,"publisher":"Index Copernicus","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2025,11,12]]},"abstract":"<ns3:p>Pancreatic ductal adenocarcinoma (PDAC) is a tumor characterized by a very poor prognosis and increasing global incidence. Environmental factors have been identified among the various causes of pancreatic cancer, while about 10\u201315% of presenting patients show a genetic predisposition towards the disease. This paper presents the current insight into the etiology and pathogenesis of cancer, as well as the principles of diagnosis and treatment of the disease. Neoadjuvant and complementary systemic treatment, as well as the principles of palliative treatment, are widely discussed. Advances in the radicalization of surgical treatment, the new options to treat post-operative complications, as well as advances in chemotherapy for pancreatic cancer have hitherto failed to dramatically improve the prognosis, even at the local stage. A breakthrough in pancreatic cancer research is still awaited.<\/ns3:p>","DOI":"10.5604\/01.3001.0055.4391","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:10:13Z","timestamp":1766045413000},"page":"51-59","source":"Crossref","is-referenced-by-count":2,"title":["Current diagnosis and treatment of pancreatic cancer"],"prefix":"10.5604","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6618-0241","authenticated-orcid":false,"given":"Jaros\u0142aw","family":"Matykiewicz","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Holy Cross Cancer Centre in Kielce, Poland, Collegium Medicum Jan Kochanowski University in Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-6695","authenticated-orcid":false,"given":"Robert","family":"Dziura","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Holy Cross Cancer Centre in Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7752-0459","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"G\u0142uszek","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Holy Cross Cancer Centre in Kielce, Poland, Department of Surgery, Hospital of the Ministry of Interior and Administration in Kielce, Poland, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Magdalenka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3689","reference":[{"key":"633727r1","doi-asserted-by":"crossref","unstructured":"Mishra N.K., Southekal S., Guda C.: Survival Analysis of Multi-Omics DataIdentifies Potential Prognostic Markers of Pancreatic Ductal Adenocarcinoma.Front Genet., 2019; 10: 624. doi: 10.3389\/fgene.2019.00624.","DOI":"10.3389\/fgene.2019.00624"},{"key":"633727r2","doi-asserted-by":"crossref","unstructured":"Siegel R.L., Miller K.D., Wagle N.S., Jemal A.: Cancer statistics, 2023. CA Cancer J Clin., 2023; 73(1): 17\u201348. doi: 10.3322\/caac.21763.","DOI":"10.3322\/caac.21763"},{"key":"633727r3","doi-asserted-by":"crossref","unstructured":"Jensen M.H., Cichosz S.L., Hejlesen O. et al.: Risk of pancreatic cancer in people with new-onset diabetes: A Danish nationwide population-based cohortstudy. Pancreatology., 2023; 23(6): 642\u2013649. doi: 10.1016\/j.pan.2023.07.001.","DOI":"10.1016\/j.pan.2023.07.001"},{"key":"633727r4","doi-asserted-by":"crossref","unstructured":"Abboud Y., Samaan J.S., Oh J. et al.: Increasing Pancreatic Cancer Incidencein Young Women in the United States: A Population-Based Time-Trend Analysis, 2001\u20132018. Gastroenterology., 2023; 164(6): 978\u2013989.e6. doi: 10.1053\/j.gastro.2023.01.022.","DOI":"10.1053\/j.gastro.2023.01.022"},{"key":"633727r5","doi-asserted-by":"crossref","unstructured":"Abbott R., Abbott T.D., Acernese F. et al.: Search for Subsolar-Mass Binaries inthe First Half of Advanced LIGO\u2019s and Advanced Virgo\u2019s Third Observing Run.Phys Rev Lett., 2022; 129(6): 061104. doi: 10.1103\/PhysRevLett.129.061104.","DOI":"10.1103\/PhysRevLett.129.061104"},{"key":"633727r6","doi-asserted-by":"crossref","unstructured":"Chang M.C., Wong J.M., Chang Y.T.: Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol., 2014; 20(9):2358\u20132364. doi: 10.3748\/wjg.v20.i9.2358.","DOI":"10.3748\/wjg.v20.i9.2358"},{"key":"633727r7","doi-asserted-by":"crossref","unstructured":"Raimondi S., Lowenfels A.B., Morselli-Labate A.M., Maisonneuve P., Pezzilli R.: Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol., 2010; 24(3): 349\u2013358. doi:10.1016\/j.bpg.2010.02.007.","DOI":"10.1016\/j.bpg.2010.02.007"},{"key":"633727r8","doi-asserted-by":"crossref","unstructured":"Ryan D.P., Hong T.S., Bardeesy N.: Pancreatic adenocarcinoma. N Engl J Med.,2014; 371(22): 2140\u20132141. doi: 10.1056\/NEJMc1412266.","DOI":"10.1056\/NEJMc1412266"},{"key":"633727r9","doi-asserted-by":"crossref","unstructured":"Bailey P., Chang D.K., Nones K. et al.: Genomic analyses identify molecularsubtypes of pancreatic cancer. Nature., 2016; 531(7592): 47\u201352. doi: 10.1038\/nature16965.","DOI":"10.1038\/nature16965"},{"key":"633727r10","doi-asserted-by":"crossref","unstructured":"Rawla P., Sunkara T., Gaduputi V.: Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol., 2019; 10(1): 10\u201327. doi:10.14740\/wjon1166.","DOI":"10.14740\/wjon1166"},{"key":"633727r11","doi-asserted-by":"crossref","unstructured":"Matykiewicz J., Adamus-Bialek W., Wawszczak-Kasza M. et al.: The known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancerrisk assessment. Sci Rep., 2025; 15(1): 1791. doi: 10.1038\/s41598-025-86249-8.","DOI":"10.1038\/s41598-025-86249-8"},{"key":"633727r12","doi-asserted-by":"crossref","unstructured":"Gluszek S., Kowalik A., Koziel D. et al.: CTRC gene polymorphism may increase pancreatic cancer risk \u2013 preliminary study. Pol Przegl Chir., 2017; 89(5):48\u201353. doi: 10.5604\/01.3001.0010.5411.","DOI":"10.5604\/01.3001.0010.5411"},{"key":"633727r13","doi-asserted-by":"crossref","unstructured":"G\u0142uszek S., Koziel D.: Genetic determination of pancreatic cancer. Stud Med.,2018; 34(2): 178\u2013182. doi: 10.5114\/ms.2018.76879.","DOI":"10.5114\/ms.2018.76879"},{"key":"633727r14","doi-asserted-by":"crossref","unstructured":"Kupfer S.S., Gupta S., Weitzel J.N., Samadder J.: AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 andBRCA2 Carriers: Commentary. Gastroenterology., 2020; 159(2): 760\u2013764.doi: 10.1053\/j.gastro.2020.03.086.","DOI":"10.1053\/j.gastro.2020.03.086"},{"key":"633727r15","doi-asserted-by":"crossref","unstructured":"Bartsch D.K., Matthai E., Mintziras I. et al.: The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)-Knowledge Gained in 20 Years.Dtsch Arztebl Int., 2021; 118(10): 163\u2013168. doi: 10.3238\/arztebl.m2021.0004.","DOI":"10.3238\/arztebl.m2021.0004"},{"key":"633727r16","doi-asserted-by":"crossref","unstructured":"Canto M.I., Harinck F., Hruban R.H. et al.: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patientswith increased risk for familial pancreatic cancer. Gut., 2013; 62(3): 339\u2013347.doi: 10.1136\/gutjnl-2012-303108.","DOI":"10.1136\/gutjnl-2012-303108"},{"key":"633727r17","doi-asserted-by":"crossref","unstructured":"Mohamed G., Munir M., Rai A., Gaddam S.: Pancreatic Cancer: Screeningand Early Detection. Gastroenterol Clin North Am., 2025; 54(1): 205\u2013221.doi: 10.1016\/j.gtc.2024.09.006.","DOI":"10.1016\/j.gtc.2024.09.006"},{"key":"633727r18","doi-asserted-by":"crossref","unstructured":"Winter K., Talar-Wojnarowska R., Dabrowski A. et al.: Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol., 2019; 14(1): 1\u201318. doi: 10.5114\/pg.2019.83422.","DOI":"10.5114\/pg.2019.83422"},{"key":"633727r19","doi-asserted-by":"crossref","unstructured":"Buckland G.R., Wilding S.A., McDonnell D., Hamady Z.Z.R.: The role of aspirinin the prevention of pancreatic cancer: A nested case-control study in the UKBiobank. Pancreatology., 2024; 24(6): 947\u2013953. doi: 10.1016\/j.pan.2024.08.005.","DOI":"10.1016\/j.pan.2024.08.005"},{"key":"633727r20","doi-asserted-by":"crossref","unstructured":"Mukherjee S., Patra A., Khasawneh H. et al.: Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic ComputedTomography Scans at a Substantial Lead Time Before Clinical Diagnosis. Gastroenterology., 2022; 163(5): 1435\u20131446.e3. doi: 10.1053\/j.gastro.2022.06.066.","DOI":"10.1053\/j.gastro.2022.06.066"},{"key":"633727r21","doi-asserted-by":"crossref","unstructured":"Xu C., Jun E., Okugawa Y. et al.: A Circulating Panel of circRNA Biomarkers forthe Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.Gastroenterology., 2024; 166(1): 178\u2013190.e16. doi: 10.1053\/j.gastro.2023.09.050.","DOI":"10.1053\/j.gastro.2023.09.050"},{"key":"633727r22","doi-asserted-by":"crossref","unstructured":"Zhang X.P., Xu S., Gao Y.X. et al.: Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenterstudy. Int J Surg., 2023; 109(4): 785\u2013793. doi: 10.1097\/JS9.0000000000000296.","DOI":"10.1097\/JS9.0000000000000296"},{"key":"633727r23","doi-asserted-by":"crossref","unstructured":"Conroy T., Pfeiffer P., Vilgrain V. et al.: Pancreatic cancer: ESMO ClinicalPractice Guideline for diagnosis, treatment and follow-up. Ann Oncol., 2023;34(11): 987\u20131002. doi: 10.1016\/j.annonc.2023.08.009.","DOI":"10.1016\/j.annonc.2023.08.009"},{"key":"633727r24","doi-asserted-by":"crossref","unstructured":"Dziura R., Macek P., Smok-Kalwat J., G\u00f3\u017ad\u017a S.: Radical therapy of resectableand borderline resectable pancreatic cancer \u2013 present state of knowledge. Dowe have sufficient data to use neoadjuvant treatment?. Stud Med., 2020; 36(2):142\u2013147. doi: 10.5114\/ms.2020.96795.","DOI":"10.5114\/ms.2020.96795"},{"key":"633727r25","doi-asserted-by":"crossref","unstructured":"van Dam J.L., Verkolf E.M.M., Dekker E.N. et al.: Perioperative or adjuvantmFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer., 2023; 23(1): 728 doi: 10.1186\/s12885-023-11141-5.","DOI":"10.1016\/j.annonc.2023.09.2632"},{"key":"633727r26","doi-asserted-by":"crossref","unstructured":"Janssen Q.P., van Dam J.L., Bonsing B.A. et al.: Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvantgemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer., 2021; 21(1): 300. doi: 10.1186\/s12885-021-08031-z.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4171"},{"key":"633727r27","doi-asserted-by":"crossref","unstructured":"Uson Junior P.L.S., Dias E.S.D., de Castro N.M. et al.: Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematicreview and meta-analysis of randomized controlled trials. ESMO Open., 2023;8(1): 100771. doi: 10.1016\/j.esmoop.2022.100771.","DOI":"10.1016\/j.esmoop.2022.100771"},{"key":"633727r28","doi-asserted-by":"crossref","unstructured":"Motoi F., Kosuge T., Ueno H. et al.: Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol., 2019; 49(2):190\u2013194. doi: 10.1093\/jjco\/hyy190.","DOI":"10.1093\/jjco\/hyy190"},{"key":"633727r29","doi-asserted-by":"crossref","unstructured":"Versteijne E., Suker M., Groothuis K. et al.: Preoperative ChemoradiotherapyVersus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.J Clin Oncol., 2020; 38(16): 1763\u20131773. doi: 10.1200\/JCO.19.02274.","DOI":"10.1200\/JCO.19.02274"},{"key":"633727r30","doi-asserted-by":"crossref","unstructured":"Sohal D.P.S., Duong M., Ahmad S.A. et al.: Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized ClinicalTrial. JAMA Oncol., 2021; 7(3): 421\u2013427. doi: 10.1001\/jamaoncol.2020.7328.","DOI":"10.1001\/jamaoncol.2020.7328"},{"key":"633727r31","doi-asserted-by":"crossref","unstructured":"Janssen Q.P., van Dam J.L., Doppenberg D. et al.: FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis bythe Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst., 2022;114(5): 695\u2013703. doi: 10.1093\/jnci\/djac018.","DOI":"10.1093\/jnci\/djac018"},{"key":"633727r32","doi-asserted-by":"crossref","unstructured":"Labori K.J., Bratlie S.O., Andersson B. et al.: Neoadjuvant FOLFIRINOX versusupfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol., 2024; 9(3):205\u2013217. doi: 10.1016\/S2468-1253(23)00405-3.","DOI":"10.1016\/S2468-1253(23)00405-3"},{"key":"633727r33","doi-asserted-by":"crossref","unstructured":"Bao Q.R., Frigerio I., Tripepi M. et al.: Prognostic value of major pathologicalresponse following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. Pancreatology., 2023; 23(3): 266\u2013274. doi: 10.1016\/j.pan.2023.02.005.","DOI":"10.1016\/j.pan.2023.02.005"},{"key":"633727r34","doi-asserted-by":"crossref","unstructured":"Eade A.V., Friedman L.R., Larrain C. et al.: ALLIANCE A021806: A Phase IIITrial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer. Ann Surg Oncol., 2024; 31(10): 6373\u20136374. doi: 10.1245\/s10434--024-15817-5.","DOI":"10.1245\/s10434-024-15817-5"},{"key":"633727r35","doi-asserted-by":"crossref","unstructured":"Reni M.: Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductaladenocarcinoma. J Clin Oncol., 2025; 43(17): Abstr LBA4004. doi: 10.1200\/JCO.2025.43.17_suppl.LBA4004.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4004"},{"key":"633727r36","doi-asserted-by":"crossref","unstructured":"Turpin A.: Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone afterFOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreaticductal adenocarcinoma (aPDAC): Primary endpoint results of a randomizedTEDOPAM GERCOR D17-01 PRODIGE 63 trial. J Clin Oncol., 2025; 43(16):Abstr 4009. doi: 10.1200\/JCO.2025.43.16_suppl.4009.","DOI":"10.1200\/JCO.2025.43.16_suppl.4009"},{"key":"633727r37","doi-asserted-by":"crossref","unstructured":"Conroy T., Hammel P., Hebbar M. et al.: FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med., 2018; 379(25): 2395\u20132406.doi: 10.1056\/NEJMoa1809775.","DOI":"10.1056\/NEJMoa1809775"},{"key":"633727r38","doi-asserted-by":"crossref","unstructured":"Isaji S., Mizuno S., Windsor J.A. et al.: International consensus on definitionand criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.Pancreatology., 2018; 18(1): 2\u201311. doi: 10.1016\/j.pan.2017.11.011.","DOI":"10.1016\/j.pan.2017.11.011"},{"key":"633727r39","unstructured":"Durlik M.: Leczenie chirurgiczne raka trzustki. In: Choroby trzustki w praktyce klinicznej, eds.: A. Madro, R. Talar-Wojnarowska. Wydawnictwo Czelej,Lublin 2022, 240\u2013249."},{"key":"633727r40","doi-asserted-by":"crossref","unstructured":"Hackert T., Strobel O., Michalski C.W. et al.: The TRIANGLE operation \u2013 radical surgery after neoadjuvant treatment for advanced pancreatic cancer:a single arm observational study. HPB (Oxford)., 2017; 19(11): 1001\u20131007.doi: 10.1016\/j.hpb.2017.07.007.","DOI":"10.1016\/j.hpb.2017.07.007"},{"key":"633727r41","doi-asserted-by":"crossref","unstructured":"Hung K.C., Chung S.J., Kwa A.L. et al.: Surgical prophylaxis in pancreatoduodenectomy: Is cephalosporin still the drug of choice in patients with biliary stentsin situ? Pancreatology., 2024; 24(6): 960\u2013965. doi: 10.1016\/j.pan.2024.07.004.","DOI":"10.1016\/j.pan.2024.07.004"},{"key":"633727r42","doi-asserted-by":"crossref","unstructured":"Liu Q., Li M., Gao Y. et al.: Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol., 2024; 9(5): 428\u2013437. doi:10.1016\/S2468-1253(24)00005-0.","DOI":"10.1016\/S2468-1253(24)00005-0"},{"key":"633727r43","doi-asserted-by":"crossref","unstructured":"Li X., Fu Z., Cao K. et al.: Vascular stent graft for the treatment of post-pancreaticoduodenectomy hemorrhage and risk factors for rebleeding. Pancreatology., 2025; 25(3): 396\u2013404. doi: 10.1016\/j.pan.2025.02.009.","DOI":"10.1016\/j.pan.2025.02.009"},{"key":"633727r44","doi-asserted-by":"crossref","unstructured":"Chen H., Wang C., Xia W. et al.: Early prediction of post-pancreatectomy acute pancreatitis after pancreaticoduodenectomy based on serum C-reactiveprotein. Pancreatology., 2025; 25(2): 208\u2013213. doi: 10.1016\/j.pan.2025.01.002.","DOI":"10.1016\/j.pan.2025.01.002"},{"key":"633727r45","doi-asserted-by":"crossref","unstructured":"Zhuang H., Zhou Z., Ma Z. et al.: Prognostic Nomogram for Patients WithPancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. Clin Med Insights Oncol., 2021; 15: 11795549211024149. doi:10.1177\/11795549211024149.","DOI":"10.1177\/11795549211024149"},{"key":"633727r46","doi-asserted-by":"crossref","unstructured":"Perinel J., Adham M.: Palliative therapy in pancreatic cancer-palliative surgery. Transl Gastroenterol Hepatol., 2019; 4: 28. doi: 10.21037\/tgh.2019.04.03.","DOI":"10.21037\/tgh.2019.04.03"},{"key":"633727r47","doi-asserted-by":"crossref","unstructured":"Rai Z.L., Ranieri V., Palmer D.H. et al.: Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE)following initial systemic chemotherapy (LAP-PIE) trial: study protocol fora feasibility randomised controlled trial. BMJ Open., 2022; 12(5): e050166.doi: 10.1136\/bmjopen-2021-050166.","DOI":"10.1136\/bmjopen-2021-050166"},{"key":"633727r48","doi-asserted-by":"crossref","unstructured":"Rai Z.L., Feakins R., Pallett L.J., Manas D., Davidson B.R.: Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of CurrentClinical Outcomes, Mechanism of Action and Opportunities for SynergisticTherapy. J Clin Med., 2021; 10(8): 1609. doi: 10.3390\/jcm10081609.","DOI":"10.3390\/jcm10081609"},{"key":"633727r49","doi-asserted-by":"crossref","unstructured":"Nishio K., Kimura K., Amano R. et al.: Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol., 2017; 15(1): 16. doi:10.1186\/s12957-016-1078-z.","DOI":"10.1186\/s12957-016-1078-z"},{"key":"633727r50","doi-asserted-by":"crossref","unstructured":"Brunner M., Wu Z., Krautz C. et al.: Current Clinical Strategies of PancreaticCancer Treatment and Open Molecular Questions. Int J Mol Sci., 2019; 20(18): 4543 doi: 10.3390\/ijms20184543.","DOI":"10.3390\/ijms20184543"},{"key":"633727r51","doi-asserted-by":"crossref","unstructured":"Sasaki A., Sakata K., Nakano K. et al.: DUPAN-2 as a Risk Factor of EarlyRecurrence After Curative Pancreatectomy for Patients With PancreaticDuctal Adenocarcinoma. Pancreas., 2023; 52(2): e110\u2013e114. doi: 10.1097\/MPA.0000000000002209.","DOI":"10.1097\/MPA.0000000000002209"}],"container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.4391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0055.4391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:08:08Z","timestamp":1779880088000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0055.4391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11,12]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0055.4391","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"value":"0032-373X","type":"print"},{"value":"2299-2847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}